← All trials
NCT05396300
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2022
- Primary completion
- May 15, 2024
- Completion date
- May 15, 2025
- First posted
- May 31, 2022
- Last posted
- Jun 2, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversitySponsor investigator
- Chongqing Precision Biotech Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.